Solan Headlines

“Ovarian Cancer Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ovarian Cancer Market.

The Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Ovarian Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight

Some of the key takeaways from the Ovarian Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Ovarian Cancer treatment therapies with a considerable amount of success over the years.

• Ovarian Cancer companies working in the treatment market are Mario Negri Institute, Tesaro, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme, Gradalis, Inc., AGO Research GmbH, Haider Mahdi, AstraZeneca, Jacobio Pharmaceuticals, SpringWorks Therapeutics, Takeda, Suzhou Suncadia Biopharmaceutical, EMD Serono Research, Hoffmann-La Roche, Anhui Provincial Cancer Hospital, Jiangsu Simcere Pharmaceutical, and others, are developing therapies for the Ovarian Cancer treatment

• Emerging Ovarian Cancer therapies in the different phases of clinical trials are- Olaparib, Niraparib, MORAb-202, Paclitaxel, Vigil, olaparib, Pembrolizumab, Olaparib, JAB-8263, Nirogacestat, TAK-853, SHR-A1921, Tuvusertib (M1774), Ipatasertib, Paclitaxel, BD0801, and others are expected to have a significant impact on the Ovarian Cancer market in the coming years.

• In October 2026, Genmab announced findings from the RAINFOL-01 trial, in which Rina-S demonstrated a confirmed objective response rate of 45.9% among 109 treated patients, including five complete responses. The median duration of response was 12.1 months. Antitumor activity was observed across varying levels of folate receptor alpha (FRα) expression, including tumors with low expression and those lacking expression. However, Rina-S remains an investigational therapy and has not yet received regulatory approval.

• In October 2026, reports highlighted preliminary clinical results for ubamatamab in heavily pretreated patients with recurrent low-grade serous ovarian cancer. Initial findings from 11 patients demonstrated an objective response rate of 73%. Although these early results are encouraging, further studies involving larger patient populations are needed to validate the treatment’s efficacy and assess the durability of its responses.

• In September 2026, The FDA granted an Investigational Device Exemption (IDE) to Mercy BioAnalytics for its Evident ovarian cancer screening test, enabling the company to advance its pivotal SOARA study following institutional review board approval. The prospective trial aims to assess the test’s performance in women at average risk of ovarian cancer. This authorization allows the company to conduct the clinical investigation but does not represent FDA approval for the test’s commercial use.

• In August 2026, The FDA granted Fast Track designation to the combination of BI-1808 and pembrolizumab for ovarian cancer. Interim Phase IIa findings in heavily pretreated patients with platinum-resistant disease demonstrated a confirmed objective response rate of 24% and a disease control rate of 56%. The ongoing study is assessing the combination’s therapeutic potential across multiple ovarian cancer subtypes, including high-grade serous and clear cell carcinoma. Fast Track designation is intended to expedite the development and regulatory review of promising therapies but does not constitute FDA approval.

• In May 2026, Researchers presented findings from a first-in-human study of AVB-001 in patients with advanced ovarian cancer. This investigational therapy employs engineered, encapsulated cells to release interleukin-2 directly into the abdominal cavity, with the goal of activating the immune system while minimizing systemic exposure. The findings offer preliminary clinical evidence supporting localized cytokine delivery as a potential therapeutic strategy. However, further studies involving larger patient populations are required to confirm the treatment’s safety and efficacy.

• In January 2026, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for treating adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a novel folate receptor alpha (FRα) antibody-drug conjugate (ADC) featuring proprietary linker technology and an exatecan payload. The Breakthrough Therapy designation is intended to accelerate the development and review of drugs for serious conditions where preliminary clinical evidence suggests the therapy may offer substantial improvement over existing treatments on clinically meaningful endpoints.

• In December 2025, Daiichi Sankyo has reported the first patient dosing in the randomization phase of the DESTINY-Ovarian01 Phase III trial, which is evaluating Enhertu (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab alone as a first-line maintenance therapy for ovarian cancer. The study targets patients with HER2-expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer who have completed initial treatment with platinum-based chemotherapy plus bevacizumab. This randomized, global, multi-center, open-label Phase III trial is designed to assess the safety and efficacy of the Enhertu (5.4 mg/kg) combination in the specified patient population.

• In November 2025, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage biopharmaceutical company advancing stenoparib (2X-121)—a unique dual PARP and WNT pathway inhibitor announced its financial results and operational progress for the third quarter ending September 30, 2025. The company noted that Q3 2025 marked significant achievements, including receiving FDA Fast Track designation for stenoparib in advanced ovarian cancer, underscoring the promise of its lead program. Allarity also shared encouraging new clinical data demonstrating a median overall survival of more than 25 months in its Phase 2 trial, a notable outcome for this challenging patient population.

• In April 2025, Corcept Therapeutics’ key Phase III ROSELLA trial evaluating oral relacorilant combined with nab-paclitaxel has successfully achieved its primary goal by showing an improvement in progression-free survival (PFS) in patients with platinum-resistant ovarian cancer. The study included 381 participants from Argentina, Brazil, Canada, Europe, Australia, and South Korea, and demonstrated a 30% reduction in the risk of disease progression for those receiving the combination therapy compared to nab-paclitaxel alone.

• In March 2025, Imunon announced that the US Food and Drug Administration (FDA) has aligned with the Phase III OVATION 3 trial protocol for IMNN-001 in ovarian cancer. IMNN-001, the company’s lead drug candidate, is being developed to treat women newly diagnosed with advanced ovarian cancer. Imunon is now opening clinical trial sites and working with investigators to begin enrolling participants.

• In March 2025, AbbVie, a US-based pharmaceutical company, has released the final analysis of its Phase III MIRASOL trial evaluating the antibody-drug conjugate (ADC) Elahere compared to chemotherapy for platinum-resistant ovarian cancer (PROC). This randomized trial examined the safety and effectiveness of the treatment in women with folate receptor alpha (FRα) positive PROC.

Ovarian Cancer Overview

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and hormones. It typically develops when abnormal cells in the ovaries grow uncontrollably and form tumors. Ovarian cancer is often referred to as a “silent” disease because its symptoms can be vague or go unnoticed until the cancer is advanced. Common symptoms may include bloating, pelvic pain, frequent urination, and difficulty eating. Early detection can be challenging, but with treatment options such as surgery, chemotherapy, and targeted therapies, the prognosis can improve, especially if caught in its early stages.

Explore the latest Ovarian Cancer pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Ovarian Cancer Clinical Trials

Emerging Ovarian Cancer Drugs Under Different Phases of Clinical Development Include:

• Olaparib: Mario Negri Institute

• Niraparib: Tesaro, Inc.

• MORAb-202: Bristol-Myers Squibb

• Paclitaxel: Merck Sharp & Dohme

• Vigil: Gradalis, Inc.

• olaparib: AGO Research GmbH

• Pembrolizumab: Haider Mahdi

• Olaparib: AstraZeneca

• JAB-8263: Jacobio Pharmaceuticals

• Nirogacestat: SpringWorks Therapeutics

• TAK-853: Takeda

• SHR-A1921: Suzhou Suncadia Biopharmaceutical

• Tuvusertib (M1774): EMD Serono Research

• Ipatasertib: Hoffmann-La Roche

• Paclitaxel: Anhui Provincial Cancer Hospital

• BD0801: Jiangsu Simcere Pharmaceutical

Ovarian Cancer Route of Administration

Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical.

Ovarian Cancer Molecule Type

Ovarian Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Ovarian Cancer Pipeline Therapeutics Assessment

• Ovarian Cancer Assessment by Product Type

• Ovarian Cancer By Stage and Product Type

• Ovarian Cancer Assessment by Route of Administration

• Ovarian Cancer By Stage and Route of Administration

• Ovarian Cancer Assessment by Molecule Type

• Ovarian Cancer by Stage and Molecule Type

DelveInsight’s Ovarian Cancer Report covers around 200+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Ovarian Cancer product details are provided in the report. Download the Ovarian Cancer pipeline report to learn more about the emerging Ovarian Cancer therapies

Some of the key companies in the Ovarian Cancer Therapeutics Market include:

Key companies developing therapies for Ovarian Cancer are – Pfizer, Daiichi Sankyo, Inc., Astellas Pharma Inc, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, ImmunoGen, OncoQuest, Lee’s Pharmaceutical, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Bayer, Xennials Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Puma Biotechnology, Inc., MaxCyte, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and others.

Ovarian Cancer Pipeline Analysis:

The Ovarian Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Ovarian Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer Treatment.

• Ovarian Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ovarian Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ovarian Cancer drugs and therapies

Ovarian Cancer Pipeline Market Drivers

• Increasing prevalence of Ovarian Cancer, increasing research and development activities, launch of novel drugs are some of the important factors that are fueling the Ovarian Cancer Market.

Ovarian Cancer Pipeline Market Barriers

• However, huge expenditure of the treatment methods, adverse effects associated with the drugs and other factors are creating obstacles in the Ovarian Cancer Market growth.

Scope of Ovarian Cancer Pipeline Drug Insight

• Coverage: Global

• Key Ovarian Cancer Companies: Mario Negri Institute, Tesaro, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme, Gradalis, Inc., AGO Research GmbH, Haider Mahdi, AstraZeneca, Jacobio Pharmaceuticals, SpringWorks Therapeutics, Takeda, Suzhou Suncadia Biopharmaceutical, EMD Serono Research, Hoffmann-La Roche, Anhui Provincial Cancer Hospital, Jiangsu Simcere Pharmaceutical, and others

• Key Ovarian Cancer Therapies: Olaparib, Niraparib, MORAb-202, Paclitaxel, Vigil, olaparib, Pembrolizumab, Olaparib, JAB-8263, Nirogacestat, TAK-853, SHR-A1921, Tuvusertib (M1774), Ipatasertib, Paclitaxel, BD0801, and others

• Ovarian Cancer Therapeutic Assessment: Ovarian Cancer current marketed and Ovarian Cancer emerging therapies

• Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers

Request for Sample PDF Report for Ovarian Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Ovarian Cancer Report Introduction

2. Ovarian Cancer Executive Summary

3. Ovarian Cancer Overview

4. Ovarian Cancer- Analytical Perspective In-depth Commercial Assessment

5. Ovarian Cancer Pipeline Therapeutics

6. Ovarian Cancer Late Stage Products (Phase II/III)

7. Ovarian Cancer Mid Stage Products (Phase II)

8. Ovarian Cancer Early Stage Products (Phase I)

9. Ovarian Cancer Preclinical Stage Products

10. Ovarian Cancer Therapeutics Assessment

11. Ovarian Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ovarian Cancer Key Companies

14. Ovarian Cancer Key Products

15. Ovarian Cancer Unmet Needs

16 . Ovarian Cancer Market Drivers and Barriers

17. Ovarian Cancer Future Perspectives and Conclusion

18. Ovarian Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services